Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02400814 · ClinicalTrials.gov registry record · Phase 1
MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer
A Phase 1 study, sponsored by Megan Daly, MD.
- Terminated
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT02400814 is a Phase 1 study that was terminated before completion, run by Megan Daly, MD. The registered enrollment target is 27 participants.
The verdict
NCT02400814, a Phase 1 study, was terminated before completion, sponsored by Megan Daly, MD.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This pilot phase I trial compares administration schedules of anti-programmed cell death-1 ligand 1 (PD-L1) monoclonal antibody MPDL3280A and stereotactic ablative radiotherapy in treating patients with stage IV non-small cell lung cancer. Monoclonal antibodies, such as anti-PD-L1 monoclonal antibody MPDL3280A, may block tumor growth in different ways by targeting certain cells. Stereotactic ablative radiotherapy, also known as stereotactic body radiation therapy, is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. Giving anti-PD-L1 monoclonal antibody MPDL3280A with stereotactic ablative radiotherapy may be a better treatment for non-small cell lung cancer. However, it is not yet known what the best administration schedule is for these treatments.
Interventions
- RADIATION Stereotactic Body Radiation Therapy
- DRUG Anti-PD-L1 Monoclonal Antibody MPDL3280A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2015-12-03 |
| Est. Completion | 2021-09-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02400814
The ClinicalTrials.gov registry entry for NCT02400814 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Megan Daly, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Stereotactic Body Radiation Therapy is the first listed.
NCT02400814 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02400814 about?
NCT02400814 is a clinical study titled "MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer". This pilot phase I trial compares administration schedules of anti-programmed cell death-1 ligand 1 (PD-L1) monoclonal antibody MPDL3280A and stereotactic ablative radiotherapy in treating patients with stage IV non-small cell lung cancer. Monoclonal antibodies, such as anti-PD-L1 monoclonal antibod...
What is the current status of trial NCT02400814?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2015-12-03. Estimated completion is 2021-09-29.
What interventions are being tested in trial NCT02400814?
The interventions under investigation include: Stereotactic Body Radiation Therapy (RADIATION), Anti-PD-L1 Monoclonal Antibody MPDL3280A (DRUG).
Who is sponsoring clinical trial NCT02400814?
This trial is sponsored by Megan Daly, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.